Welcome to our dedicated page for Organovo Holding news (Ticker: ONVO), a resource for investors and traders seeking the latest updates and insights on Organovo Holding stock.
Organovo Holdings, Inc. (Nasdaq: ONVO) generates news as a clinical stage biotechnology company that combines proprietary three-dimensional (3D) human tissue technology with drug development efforts. Company announcements describe a focus on novel treatment approaches in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, and on drug candidates that are demonstrated to be effective in 3D human tissues.
News related to Organovo often covers updates on its lead clinical stage drug FXR314 and its broader FXR program. Disclosures have included Phase 2 results for FXR314 in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), highlighting liver fat reduction, safety, and tolerability, as well as preclinical data in 3D human cellular models of IBD. Additional coverage includes the announcement that Eli Lilly and Company will acquire Organovo’s FXR program, including FXR314, with upfront and potential milestone payments and Lilly assuming responsibility for future clinical development.
Investors and followers of ONVO-related news can also find information on corporate actions and capital markets activity. Recent press releases have discussed a 1-for-12 reverse stock split intended to support compliance with Nasdaq Capital Market listing requirements, issuance of additional shares through warrant exercises and at-the-market stock sales, and updates on preliminary cash balances and net cash utilization. These items provide context on the company’s financial position and listing status.
Another significant theme in Organovo’s news flow is its transition to operate under the name VivoSim Labs, Inc. The company has announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc., and that its common stock will begin trading under the new ticker symbol VIVS on the Nasdaq Capital Market. Related announcements from VivoSim Labs describe plans to offer liver and intestinal toxicology insights using organoid models from human donor cells and AI-based computational modeling, reflecting how Organovo’s legacy technology is being positioned going forward.
For readers tracking ONVO, this news stream provides historical and transitional context, ranging from clinical data and program transactions to listing-related developments and the evolution of the business identity toward VivoSim Labs, Inc.
Summary not available.
Summary not available.
Summary not available.
Organovo Holdings, Inc. (NASDAQ: ONVO) has announced its clinical program for FXR314, an FXR agonist that has completed initial trials with positive safety and tolerability results. The drug is approved for a Phase 2 trial targeting ulcerative colitis. The company emphasizes that FXR314 could be a superior option compared to existing FXR-directed therapies, aiming to minimize dose-limiting toxicity. Additionally, the company updated its timeline, moving the start of Phase 1 trials to 2025, with further guidance on Phase 2 forthcoming. Organovo specializes in developing therapies utilizing advanced 3D human tissue models.
Organovo Holdings (ONVO) has achieved a significant milestone in developing a three-dimensional model for inflammatory bowel disease (IBD), particularly Crohn's disease. The model has been validated for target identification and therapeutic opportunities, demonstrating the ability to reproduce disease characteristics and reduce symptoms through targeted treatments. Organovo aims to advance at least one target to medicinal chemistry by the end of 2022, seeking to create a proprietary drug for Crohn's disease, a condition affecting over 1 million individuals in North America.
Organovo Holdings, focusing on innovative 3D tissue models for drug development, announced Executive Chairman Keith Murphy's participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company aims to advance drug development for Crohn’s Disease, having recently established its first 3D tissue model. A corporate presentation will be webcast on September 12, 2022, at 7:00 AM ET. Investors can access the archived presentation on Organovo's website for 90 days.
Organovo Holdings (ONVO) announces the postponement of its 2022 Annual Meeting from September 7 to October 12, 2022, at 9:00 AM PT. This decision was made after the company received less than 35% of proxies by the previous record date, July 15, 2022. The new record date is set for September 7, 2022. The meeting will be conducted virtually to enhance stockholder participation. An amended proxy statement will be filed promptly with the SEC, providing updated information regarding the meeting.
Organovo Holdings, Inc. (Nasdaq: ONVO) has successfully advanced its first inflammatory bowel disease (IBD) model for Crohn’s disease, marking a significant step in drug discovery. The model demonstrates key aspects of patient biology and is positioned to identify therapeutics. The company aims to complete target validation by March 2023, with a goal to file for an investigational new drug (IND) application by 2025. Organovo is positioning itself to leverage its 3D tissue technologies for innovative drug development, focusing on several pipeline programs for IBD.
Organovo Holdings (Nasdaq: ONVO) has announced a licensing agreement with BICO, allowing the latter to utilize Organovo's foundational patent portfolio in 3D bioprinting. This collaboration marks a significant step, as it resolves previous legal disputes over potential patent infringements. Under this agreement, all civil actions regarding these patents are dismissed. The partnership aims to enhance the capabilities of BICO's product lines, facilitating further advancements in 3D bioprinting technology.
Organovo Holdings (Nasdaq: ONVO) has partnered with BICO, granting them a broad license to its foundational patents in 3D bioprinting. This agreement resolves prior legal disputes between the two companies regarding patent infringement. Organovo's technology aims to create customized 3D human tissues for drug development, focusing on complex disease models. The company views this partnership as a significant move to broaden the impact of its bioprinting technology and support the growth of BICO's product lines.